Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 2/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7733339 | 1.00 | GID4 (0.41) | GID4SMYD3TNKSPARP1PARP2 | |
| SCHEMBL7732752 | 0.93 | GID4 (0.41) | GID4SMYD3SCN10AEGLN1HDAC6 | |
| SCHEMBL7729019 | 0.83 | SMYD3 (0.41) | GID4SMYD3TACR1EGLN1POLB | |
| SCHEMBL10173678 | 0.83 | GID4 (0.43) | GID4SCN10AHDAC6ALDH1A1GSK3B | |
| SCHEMBL14899093 | 0.82 | GID4 (0.44) | GID4SCN10ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7729500 | 0.82 | ALDH1A1 (0.40) | CYP1A2CYP3A4SMN1; SMN2POLBTDP1 | |
| SCHEMBL7723308 | 0.81 | CACNA1G (0.40) | GID4TNKSPARP1PARP2CYP1A2 | |
| SCHEMBL7723513 | 0.81 | CACNA1G (0.40) | GID4TNKSPARP1PARP2CYP1A2 | |
| SCHEMBL7732457 | 0.80 | SCN10A (0.35) | SCN10ASMN1; SMN2POLBTDP1ALDH1A1 | |
| SCHEMBL7732462 | 0.80 | SCN10A (0.35) | SCN10ASMN1; SMN2POLBTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11419834-B2 | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide | RHODE ISLAND HOSPITAL (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210137948-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2021-05-13 | — | — | US | disclosed |
| EP-3773602-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2021-02-17 | — | — | EP | disclosed |
| US-20200268693-A1 | METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE | RHODE ISLAND HOSPITAL | 2020-08-27 | — | — | US | disclosed |
| US-20190328687-A1 | Antibacterial Compounds | VICTORIA LINK LIMITED (NZ) | 2019-10-31 | — | — | US | disclosed |
| WO-2019192968-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2019-10-10 | — | — | WO | disclosed |
| EP-3220919-A1 | ANTIBACTERIAL COMPOUNDS | Victoria Link Limited (NZ) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016080846-A1 | ANTIBACTERIAL COMPOUNDS | COPP JANINE NAOMI (NZ) | 2016-05-26 | — | — | WO | disclosed |
| US-8431597-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2012-06-21 | — | — | US | disclosed |
| US-8148401-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2170860-A2 | BENZIMIDAZOLE DERIVATIVES | Pfizer Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009004427-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268693-A1 | METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE | MALT1, SI, BCL6 | GID4 1198/4885SMYD3 1096/4885TNKS 4221/4885 |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | GID4 3978/4885SMYD3 707/4885TNKS 2677/4885 |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | GID4 3978/4885SMYD3 707/4885TNKS 2677/4885 |
| US-11419834-B2 | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide | MALT1, SI, BCL6 | GID4 1198/4885SMYD3 1096/4885TNKS 4221/4885 |
| US-20210137948-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | MGLL, NIT2, SI | GID4 257/4885SMYD3 2722/4885TNKS 3560/4885 |
| US-20190328687-A1 | Antibacterial Compounds | SHARPIN, FDPS, BROX | GID4 2026/4885SMYD3 1536/4885TNKS 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.